Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes

Sun Ok Song, You Cheol Hwang, Kyu Jeung Ahn, Bong Soo Cha, Young Duk Song, Dae Wook Lee, byungwan lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: A1chieve® (ClinicalTrials.gov identifier NCT00869908) was a 24-week observational study evaluating certain insulin analogs and not insulin analogs in general in 66,726 people with type 2 diabetes (T2D) in routine clinical care in 28 non-Western countries. This study demonstrated that insulin analogs improved self-management and metabolic control in patients with T2D. We investigated the effectiveness and clinical characteristics of patients with T2D showing better response to basal insulin (BI) (detemir), using data from the A1chieve study performed in Korea. Methods: Subjects were classified into two groups according to the achievement of target glycated hemoglobin (A1c) level of <7.5%. Multivariate logistic regression analysis was performed to determine the variables independently associated with the achievement of target A1c level. Results: Baseline A1c, postprandial glucose (PPG), difference between PPG and fasting plasma glucose, and duration of diabetes were independently associated with better response to BI after adjusting for other risk factors. Compared to patients with BI use at evening, those who took BI in the morning demonstrated a larger reduction in A1c level. Conclusion: Once-daily BI therapy appears to be effective in Korean subjects with type 2 diabetes who had a shorter duration of diabetes and a smaller postprandial glucose excursion. Funding: Novo Nordisk Pharma Korea and Novo Nordisk International Operations.

Original languageEnglish
Pages (from-to)547-558
Number of pages12
JournalDiabetes Therapy
Volume6
Issue number4
DOIs
Publication statusPublished - 2015 Dec 1

Fingerprint

Type 2 Diabetes Mellitus
Insulin
Glucose
Korea
Therapeutics
Glycosylated Hemoglobin A
Self Care
Observational Studies
Fasting
Logistic Models
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Song, Sun Ok ; Hwang, You Cheol ; Ahn, Kyu Jeung ; Cha, Bong Soo ; Song, Young Duk ; Lee, Dae Wook ; lee, byungwan. / Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes. In: Diabetes Therapy. 2015 ; Vol. 6, No. 4. pp. 547-558.
@article{03205d23821f485aaa54ecfd456618ba,
title = "Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes",
abstract = "Introduction: A1chieve{\circledR} (ClinicalTrials.gov identifier NCT00869908) was a 24-week observational study evaluating certain insulin analogs and not insulin analogs in general in 66,726 people with type 2 diabetes (T2D) in routine clinical care in 28 non-Western countries. This study demonstrated that insulin analogs improved self-management and metabolic control in patients with T2D. We investigated the effectiveness and clinical characteristics of patients with T2D showing better response to basal insulin (BI) (detemir), using data from the A1chieve study performed in Korea. Methods: Subjects were classified into two groups according to the achievement of target glycated hemoglobin (A1c) level of <7.5{\%}. Multivariate logistic regression analysis was performed to determine the variables independently associated with the achievement of target A1c level. Results: Baseline A1c, postprandial glucose (PPG), difference between PPG and fasting plasma glucose, and duration of diabetes were independently associated with better response to BI after adjusting for other risk factors. Compared to patients with BI use at evening, those who took BI in the morning demonstrated a larger reduction in A1c level. Conclusion: Once-daily BI therapy appears to be effective in Korean subjects with type 2 diabetes who had a shorter duration of diabetes and a smaller postprandial glucose excursion. Funding: Novo Nordisk Pharma Korea and Novo Nordisk International Operations.",
author = "Song, {Sun Ok} and Hwang, {You Cheol} and Ahn, {Kyu Jeung} and Cha, {Bong Soo} and Song, {Young Duk} and Lee, {Dae Wook} and byungwan lee",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s13300-015-0140-0",
language = "English",
volume = "6",
pages = "547--558",
journal = "Diabetes Therapy",
issn = "1869-6953",
publisher = "Springer Publishing Company",
number = "4",

}

Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes. / Song, Sun Ok; Hwang, You Cheol; Ahn, Kyu Jeung; Cha, Bong Soo; Song, Young Duk; Lee, Dae Wook; lee, byungwan.

In: Diabetes Therapy, Vol. 6, No. 4, 01.12.2015, p. 547-558.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes

AU - Song, Sun Ok

AU - Hwang, You Cheol

AU - Ahn, Kyu Jeung

AU - Cha, Bong Soo

AU - Song, Young Duk

AU - Lee, Dae Wook

AU - lee, byungwan

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Introduction: A1chieve® (ClinicalTrials.gov identifier NCT00869908) was a 24-week observational study evaluating certain insulin analogs and not insulin analogs in general in 66,726 people with type 2 diabetes (T2D) in routine clinical care in 28 non-Western countries. This study demonstrated that insulin analogs improved self-management and metabolic control in patients with T2D. We investigated the effectiveness and clinical characteristics of patients with T2D showing better response to basal insulin (BI) (detemir), using data from the A1chieve study performed in Korea. Methods: Subjects were classified into two groups according to the achievement of target glycated hemoglobin (A1c) level of <7.5%. Multivariate logistic regression analysis was performed to determine the variables independently associated with the achievement of target A1c level. Results: Baseline A1c, postprandial glucose (PPG), difference between PPG and fasting plasma glucose, and duration of diabetes were independently associated with better response to BI after adjusting for other risk factors. Compared to patients with BI use at evening, those who took BI in the morning demonstrated a larger reduction in A1c level. Conclusion: Once-daily BI therapy appears to be effective in Korean subjects with type 2 diabetes who had a shorter duration of diabetes and a smaller postprandial glucose excursion. Funding: Novo Nordisk Pharma Korea and Novo Nordisk International Operations.

AB - Introduction: A1chieve® (ClinicalTrials.gov identifier NCT00869908) was a 24-week observational study evaluating certain insulin analogs and not insulin analogs in general in 66,726 people with type 2 diabetes (T2D) in routine clinical care in 28 non-Western countries. This study demonstrated that insulin analogs improved self-management and metabolic control in patients with T2D. We investigated the effectiveness and clinical characteristics of patients with T2D showing better response to basal insulin (BI) (detemir), using data from the A1chieve study performed in Korea. Methods: Subjects were classified into two groups according to the achievement of target glycated hemoglobin (A1c) level of <7.5%. Multivariate logistic regression analysis was performed to determine the variables independently associated with the achievement of target A1c level. Results: Baseline A1c, postprandial glucose (PPG), difference between PPG and fasting plasma glucose, and duration of diabetes were independently associated with better response to BI after adjusting for other risk factors. Compared to patients with BI use at evening, those who took BI in the morning demonstrated a larger reduction in A1c level. Conclusion: Once-daily BI therapy appears to be effective in Korean subjects with type 2 diabetes who had a shorter duration of diabetes and a smaller postprandial glucose excursion. Funding: Novo Nordisk Pharma Korea and Novo Nordisk International Operations.

UR - http://www.scopus.com/inward/record.url?scp=84949223457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949223457&partnerID=8YFLogxK

U2 - 10.1007/s13300-015-0140-0

DO - 10.1007/s13300-015-0140-0

M3 - Article

VL - 6

SP - 547

EP - 558

JO - Diabetes Therapy

JF - Diabetes Therapy

SN - 1869-6953

IS - 4

ER -